For years the injectable conversation was about volume: where to add it, how much, how instantly. The patient came in, the syringe went in, and the result was visible in the mirror before they left. That model isn't disappearing, but the center of gravity is moving, and the direction is unmistakable — toward products that prompt the body to build its own collagen over time rather than simply filling space today. Biostimulators are eating filler's lunch, and the practices adapting their consult, their pricing, and their inventory to that shift are positioning themselves to own the higher-value patient. The ones anchored entirely to instant volume are serving a preference that's quietly shrinking.
Injectables
Biostimulator Supremacy: Why Sculptra-Class Products Are Eating Filler's Lunch
The injectable conversation is shifting from instant volume to collagen built over time — and the practices that adapt their consult, pricing, and inventory to the biostimulator era will own the higher-value patient.
